BioWa, Inc. of Princeton, NJ (USA) and Lonza Pharma & Biotech of Basel (CH) today announced that they have entered into a licensing agreement with Tillotts Pharma AG of Rheinfelden (CH). The licensing agreement is of high strategic importance as it brings Tillotts one step further toward the goal of successfully developing a new antibody-based therapy for the treatment of people with gastrointestinal (GI) diseases. Tillotts has licensed the companies’ POTELLIGENT® CHOK1SVTM Cell Line Technology for use in the research…